DorsaVi Ltd (ASX: DVL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
DorsaVi Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$38.34 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.13 billion
Earnings per share
-0.002
Dividend per share
N/A
Year To Date Return
N/A
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
DorsaVi Ltd (ASX: DVL)
Latest News
Share Market News
Why the Dorsavi (ASX:DVL) share price is flying 22% higher today
Share Market News
Why the Dorsavi share price rocketed 277% higher yesterday
⏸️ Investing
Why these 4 ASX shares have tumbled lower today
⏸️ Investing
Dorsavi Ltd share price jumps 8% on FDA clearance
⏸️ Investing
The Dorsavi Ltd share price just fell 16% to a 52-week low
⏸️ Investing
Why these 4 ASX shares have sunk like stones today
⏸️ Investing
3 speculative micro-cap shares that could make you a fortune
⏸️ Investing
Why tech share Dorsavi Ltd surged higher today
⏸️ Investing
ASX 200 soars: 13 shares you should have been watching
⏸️ Investing
Why Dorsavi Ltd is one of 5 shares SINKING today
⏸️ Investing
5 explosive growth shares I will be watching in 2017
⏸️ Investing
5 shares under $5 with massive growth potential
1❯
DVL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About DorsaVi Ltd
DorsaVi Ltd is engaged in the development and sale of motion analysis technologies. Its technologies are commercialized via license, sale, or fixed-fee consultancy. The company makes wearable sensors, software, and sophisticated algorithmsthat measure movement and muscle activation at around 200 frames per second. The company's products include ViSafe (Workplace), ViMove (Clinic), and others. The firm operates in two reportable segments: Clinical and Workplace. The majorityof its revenue is generated from the Clinical segment. Geographically, the company derives maximum revenue from the United States of America, and the rest from Australia and Europe.
DVL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 09 Feb 2026 | $0.03 | $0.00 | 0.00% | 397,933 | $0.03 | $0.03 | $0.03 |
| 06 Feb 2026 | $0.03 | $0.00 | 0.00% | 864,770 | $0.03 | $0.03 | $0.03 |
| 05 Feb 2026 | $0.04 | $0.00 | 0.00% | 640,733 | $0.04 | $0.04 | $0.04 |
| 04 Feb 2026 | $0.04 | $0.00 | 0.00% | 352,819 | $0.04 | $0.04 | $0.04 |
| 03 Feb 2026 | $0.04 | $0.00 | 0.00% | 485,799 | $0.04 | $0.04 | $0.04 |
| 02 Feb 2026 | $0.04 | $0.00 | 0.00% | 1,053,091 | $0.04 | $0.04 | $0.03 |
| 30 Jan 2026 | $0.04 | $0.00 | 0.00% | 1,713,254 | $0.04 | $0.04 | $0.03 |
| 29 Jan 2026 | $0.04 | $0.00 | 0.00% | 1,163,597 | $0.04 | $0.04 | $0.04 |
| 28 Jan 2026 | $0.04 | $0.00 | 0.00% | 8,062,475 | $0.04 | $0.04 | $0.04 |
| 22 Jan 2026 | $0.04 | $0.00 | 0.00% | 7,299,736 | $0.04 | $0.04 | $0.04 |
| 21 Jan 2026 | $0.04 | $0.00 | 0.00% | 6,979,141 | $0.04 | $0.04 | $0.04 |
| 20 Jan 2026 | $0.04 | $0.00 | 0.00% | 2,263,454 | $0.04 | $0.04 | $0.04 |
| 19 Jan 2026 | $0.04 | $0.00 | 0.00% | 400,616 | $0.04 | $0.04 | $0.04 |
| 16 Jan 2026 | $0.04 | $0.00 | 0.00% | 499,998 | $0.04 | $0.04 | $0.04 |
| 15 Jan 2026 | $0.04 | $0.00 | 0.00% | 502,039 | $0.04 | $0.04 | $0.04 |
| 14 Jan 2026 | $0.04 | $0.00 | 0.00% | 1,304,678 | $0.03 | $0.04 | $0.03 |
| 13 Jan 2026 | $0.04 | $0.00 | 0.00% | 1,205,394 | $0.04 | $0.04 | $0.03 |
| 12 Jan 2026 | $0.04 | $0.00 | 0.00% | 664,361 | $0.04 | $0.04 | $0.03 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 27 Jun 2025 | Andrew Ronchi | Issued | 500,000 | $8,000 |
Conversion of securities.
|
| 27 Jun 2025 | Andrew Ronchi | Expiry | 500,000 | $8,000 |
As advised by the company. Lapsed, 500,000 Rights
|
| 27 Jun 2025 | Andrew Ronchi | Exercise | 500,000 | $8,000 |
Conversion of securities.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Gernot Kurt Abl | Non-Executive DirectorNon-Executive Chairman | Mar 2024 |
Mr Abl's background is in law, corporate finance, and strategic consulting. Gernot has more than 20 years of entrepreneurial, business strategy, and investment experience. Gernot has commercial and investing experience and has worked with early-stage businesses, across industries, to help commercialise, grow, and increase the value of the business for all stakeholders. Gernot is also on the board of and advises several businesses, ranging from early-stage pre-revenue companies through to early-stage ASX-listed companies.
|
| Mr Leigh Daniel Travers | Non-Executive Director | Dec 2024 |
Mr Travers is an executive with over a decade of experience building products and fostering strategic networks in the digital asset and technology industries. Leigh currently serves as the Director of Emerging Markets at Animoca Brands, a Hong Kong-based Web3 investment and venture company with a portfolio of over 600 projects. In this role, he oversees investments and partnerships while advising the leadership team on regulatory and compliance strategies. Previously, Leigh was the CEO of Binance Australia (2021-2023), where he led one of the region's fastest-growing fintech companies, scaling its customer base from 500,000 to 1 million users and driving trading volumes exceeding several billion dollars per week. Leigh has also served as a Director of Banxa Holdings Inc., a Web3 payments infrastructure company, which was acquired by OSL in Group Ltd in 2025.
|
| Mr Vineet Agarwal | Non-Executive Director | Sep 2024 |
Mr Agarwal is a professional with commercial experience spanning over 18 years in the technology sector. Mr Agarwal is currently Product Management Director at Advanced Micro Devices (NASDAQ:AMD), where he has overseen the management and product launch of the Ryzen Client Product line. At AMD, Mr Agarwal was in the development of the Ryzen AI, which integrates advanced AI capabilities directly into central processing units. Prior to AMD, Mr. Agarwal held strategic roles at Qualcomm (NASDAQ:QCOM), including Director of Program Management and Senior Manager, driving the development of QCOM's Snapdragon platform.
|
| Mr Justin Mouchacca | Company Secretary | Sep 2023 |
-
|
| Mr Mathew Regan | Chief Executive Officer | Nov 2025 |
-
|
| Mathew Regan | Chief Executive Officer |
-
|
|
| Justin Mouchacca | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Ifrah Nishat | 91,075,928 | 8.09% |
| Ms Chunyan Niu | 58,994,271 | 5.24% |
| Mr Bilal Ahmad | 53,100,000 | 4.72% |
| Mr Sufian Ahmad | 50,076,924 | 4.45% |
| Starfish Technology Fund II Nominees A Pty Ltd | 48,763,230 | 4.33% |
| Starfish Technology Fund II Nominees A Pty Ltd i | 48,763,229 | 4.33% |
| Clayton Capital Pty Ltd | 45,136,174 | 4.01% |
| Mishtalem Pty Ltd | 45,000,000 | 4.00% |
| Kobala Investments Pty Ltd (Fernando Edward Family A/C) | 42,875,000 | 3.81% |
| Hall Capital Finance Pty Ltd (Phoenix Microxap A/C) | 25,123,077 | 2.23% |
| Mr Fadi Diab | 22,797,085 | 2.03% |
| Mrs Stacey Liat Pevcic | 22,307,691 | 1.98% |
| Aaron Chong Soo Ahn | 20,000,000 | 1.78% |
| Tanarny Super Fund Pty Ltd (Tanarny Super Fund A/C) | 16,916,418 | 1.50% |
| David D Pevcic | 15,625,000 | 1.39% |
| Kingsbury Wealth Pty Ltd (Kingsbury Invest Unit A/C) | 14,825,000 | 1.32% |
| Mr Mobeen Iqbal | 14,000,000 | 1.24% |
| MGL Corp Pty Ltd | 12,740,556 | 1.13% |
| Ddpevcic (WA) Pty Ltd (Dominic Family A/C) | 12,590,909 | 1.12% |
| Evolution Capital Advisors Pty Ltd | 12,000,000 | 1.07% |
